Solventum Corp (SOLV)
割安ファンダメンタル
64
株価
$88.15
時価総額
$15.24B
パート1 · 企業の価値
概要
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
貸借対照表と流動性
売上高
$8.31B
直近12か月（2026/6/30まで）
純利益
$1.43B
直近12か月（2026/6/30まで）
フリーキャッシュフロー
$-10M
自己資本合計
$5.05B
負債合計
$9.24B
流動比率
1.02
利払い倍率
-
負債/EBITDA
1.98
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$126.13
現在株価
$88.15
安全マージン
+30.1%
適正価値レンジ
$81.98 - $170.27
使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。
推定方法
バリュエーション指標
P/E レシオ
10.76
ROE
30.8%
P/B レシオ
3.13
P/FCF
-
粗利益率
54.7%
ROIC
15.5%
収益性レーダー
価値創造（経済的モート）
ROIC
15.5%
WACC
6.3%
ROIC − WACC
+9.2 pp
ROICが資本コストを上回っています。企業は株主のために価値を創出しています。
ファンダメンタル分析基準
合格（15）
- EPS shows upward trend
- Price CAGR 15.07%
- ROIC 15.5%
- Gross Margin 54.7%
- Debt/Equity ratio
- Operating Margin 25.0%
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 29.0%
- Analyst Consensus 59% Buy
- Earnings Surprise avg 11.0%
- Share Dilution 1.0%
- Net Margin Trend 17.3% vs 4.5%
- Piotroski F-Score 7/9
不合格（7）
- EPS CAGR 4.51%
- P/B Ratio 3.13
- Positive Free Cash Flow
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Fairly valued)
- Earnings Quality (OCF/NI) 0.15
データなし（6）
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-スコア
財務健全性が高い
利益の質
低品質：会計処理を調査してください
株式希薄化
株式数は安定している
機関投資家の保有
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Mr. Bryan C. Hanson | CEO & Director | 58 |
| Mr. Wayde D. McMillan | Executive VP & CFO | 55 |
| Ms. Amy Landucci | Chief Information & Digital Officer | 50 |
| Ms. Marcela A. Kirberger | Chief Corporate & Legal Affairs Officer & Corporate Secretary | 58 |
| Ms. Heather L. Knight | Chief Commercial Officer | 53 |
| Mr. Neil C. Zieselman | Senior VP, Controller & Chief Accounting Officer | 49 |
| Ms. Amy Wakeham | Senior Vice President of Investor Relations & External Finance Communications | - |
| Ms. Kate Dobbs | Chief Communications & Corporate Marketing Officer | - |
| Ms. Rachel H. Ellingson | Chief Strategy & Corporate Development Officer | 55 |
| Ms. Tammy L. Gomez | Chief Human Resources Officer | 52 |
監査リスク
10
取締役会リスク
3
報酬リスク
8
株主権利リスク
6
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
業績推移
via SEC EDGAR
Latest News
Recent headlines for SOLV, sourced from Markets Gazette.
- 2/26/2026NEUTRALSolventum (SOLV) Q4 2025 Earnings Call Transcript
The transcript for Solventum Corporation's (SOLV) fourth-quarter 2025 earnings call has been made available, marking a routine event in the company's financial calendar. Solventum, a healthcare technology spin-off from 3M, is under investor scrutiny for its performance post-separation. While the release of the transcript is a standard step for transparency, the absence of the actual earnings content prevents an in-depth analysis. Investors are awaiting the detailed financial figures and future outlook to assess the business trajectory and potential implications for share value. Currently, the mere availability of the transcript, without the underlying data, provides no clear directional guidance for the market.
via Markets Gazette